Baxter International (BAX) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.55 per share a year ago.
Baxter International, Henry Schein and IDEXX Laboratories are included in this Analyst Blog.
Heightened volatility on Wall Street means contrarian stock picks can be a game-changer for savvy investors. A contrarian investing strategy involves buying overlooked assets with the expectation that they will eventually increase in value.
MedTech companies' quarterly results are likely to be strong on a sequential basis. Let's see how BAX, HSIC and IDXX are placed ahead of their earnings releases.
Get a deeper insight into the potential performance of Baxter (BAX) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Baxter (BAX) launches the Helion Integrated Surgical System in Thailand, aiming to streamline operating room efficiency and enhance surgical team connectivity with cutting-edge technology.
Baxter has been a poor performer over the last year. The stock now trades with an extremely low valuation relative to the stock's historical performance. Recently, the company raised guidance, which points to double-digit earnings growth. Analysts seem to believe this growth is sustainable.
Shares of Baxter International Inc (NYSE:BAX) are down 2.9% at $34.28, after a downgrade from Morgan Stanley to "underweight" from "equal weight," with a price-target cut to $30 from $39.
Shares of Baxter (BAX) are showing signs of stability after falling in the first half of 2024. Let's see what is driving investors' sentiment for the company.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Shares of Baxter International BAX have gained 2.8% since Jun 26, after the company announced the recall of its Life2000 Ventilation System. Though the share price had declined following the news, it recovered following reports of potential discussion on divestment of BAX's kidney care segment.
Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.